gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Neuroblastoma RAS viral

N-ras
This is an N-ras oncogene encoding a membrane protein that shuttles between the Golgi apparatus and the plasma membrane. This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex. The encoded protein, which has intrinsic GTPase activity, is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase activating protein. Mutations in this gene have been associated with somatic rectal cancer, follicular thyroid cancer, autoimmune lymphoproliferative syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia. [provided by RefSeq, Jun 2011] (from NCBI)
Top mentioned proteins: BRAF, KRAS, HAD, CAN, EGFR
Papers using N-ras antibodies
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
Supplier
Najbauer Joseph, In PLoS ONE, 2008
... ERK2, p-ERK1/2 (Thr202/Tyr204), MEK1, MEK2 and p-MEK1/MEK2 (Ser217/221) (Cell Signaling Technology, Beverly, MA); BRAF and NRAS (F-7; Santa Cruz Biotechnology, Santa Cruz, CA); KRAS ...
Papers on N-ras
Frequent BCOR Aberrations in Extranodal NK/T-Cell Lymphoma, Nasal Type.
New
Takeuchi et al., Tokyo, Japan. In Genes Chromosomes Cancer, Feb 2016
We identified several recurrent somatic mutations involving BCOR (32%), TP53 (16%), DDX3X (12%), FAT4 (8%), NRAS (8%), MLL3 (12%) and MIR17HG (8%).
Kras Is Critical for B Cell Lymphopoiesis.
New
Wang et al., Beijing, China. In J Immunol, Feb 2016
UNASSIGNED: The three major Ras members, Kras, Hras, and Nras, are highly homologous and individual Ras genes can have distinct biological functions.
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.
New
Ortiz-Urda et al., San Francisco, United States. In Oncotarget, Feb 2016
UNASSIGNED: Oncogenic NRAS mutations are frequent in melanoma and lead to increased downstream signaling and uncontrolled cell proliferation.
Timing of the loss of PTEN protein determines disease severity in a mouse model of myeloid malignancy.
New
Emanuel et al., Little Rock, United States. In Blood, Feb 2016
JMML leukemogenesis is linked to a hyperactivated RAS pathway, with driver mutations in the KRAS, NRAS, NF1, PTPN11, or CBL genes.
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.
Review
New
Impact
Schilsky et al., Alexandria, United States. In J Clin Oncol, Feb 2016
These evaluated the outcomes for patients with mCRC with no mutation detected or presence of mutation in additional exons in KRAS and NRAS.
Myelodysplastic syndromes: Contemporary review and how we treat.
Review
New
Tefferi et al., Rochester, United States. In Am J Hematol, Jan 2016
With the advent of next generation sequencing, recurrent somatic mutations in genes involved in epigenetic regulation (TET2, ASXL1, EZH2, DNMT3A, IDH1/2), RNA splicing (SF3B1, SRSF2, U2AF1, ZRSR2), DNA damage response (TP53), transcriptional regulation (RUNX1, BCOR, ETV6) and signal transduction (CBL, NRAS, JAK2) have been identified in MDS.
MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma.
Review
New
Avan et al., Mashhad, Iran. In Eur J Cancer, Jan 2016
let-7a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR-214, miR-221 and 222, has been recognised to be linked with melanoma-associated genes such as NRAS, microphthalmia-associated transcription factor, receptor tyrosine kinase c-KIT, AP-2 transcription factor, etc.
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
New
Impact
Saltz et al., Houston, United States. In J Clin Oncol, Jan 2016
In contrast to prior expectations, concurrent KRAS and NRAS mutations were detected at low allele frequency in a subset of the patients' tumors (median, 0.21% allele frequency) and were apparent mechanisms of acquired resistance in vemurafenib-sensitive patient-derived xenograft models.
Impact of somatic mutations on patterns of metastasis in colorectal cancer.
Review
New
Yaeger et al., New York City, United States. In J Gastrointest Oncol, Dec 2015
In this review, we describe our current understanding of associations between mutational activation of the KRAS, BRAF, PIK3CA, and NRAS oncogenes and clinical outcomes and metastatic patterns of mCRC.
Follicular thyroid carcinoma with NRAS Q61K and GNAS R201H mutations that had a good (131)I treatment response.
New
Chang et al., Taipei, Taiwan. In Endocrinol Diabetes Metab Case Rep, Dec 2015
UNLABELLED: We report a case of follicular thyroid carcinoma with concomitant NRAS p.Q61K and GNAS p.R201H mutations, which manifested as a 13.5 cm thyroid mass with lung, humerus and T9 spine metastases, and exhibited good response to radioactive iodine treatment.
The Genetic Evolution of Melanoma from Precursor Lesions.
New
Impact
Bastian et al., Australia. In N Engl J Med, Dec 2015
Unequivocally benign lesions harbored BRAF V600E mutations exclusively, whereas those categorized as intermediate were enriched for NRAS mutations and additional driver mutations.
The genomic landscape of juvenile myelomonocytic leukemia.
New
Impact
Loh et al., San Francisco, United States. In Nat Genet, Nov 2015
Mutations in NF1, NRAS, KRAS, PTPN11 or CBL occur in 85% of patients, yet there are currently no risk stratification algorithms capable of predicting which patients will be refractory to conventional treatment and could therefore be candidates for experimental therapies.
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
New
Impact
Zuber et al., Vienna, Austria. In Nature, Oct 2015
To identify factors involved in primary and acquired BET resistance in leukaemia, here we perform a chromatin-focused RNAi screen in a sensitive MLL-AF9;Nras(G12D)-driven AML mouse model, and investigate dynamic transcriptional profiles in sensitive and resistant mouse and human leukaemias.
Identification of novel pathogenic gene mutations in pediatric acute myeloid leukemia by whole-exome resequencing.
Review
Shiba, In Rinsho Ketsueki, 2014
Many of the recurrent mutations identified in this study involved previously reported targets in AML, such as FLT3, CEBPA, KIT, CBL, NRAS, WT1 and EZH2.
Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.
Review
Rogler et al., Zürich, Switzerland. In Swiss Med Wkly, 2014
Now data show that neuroblastoma RAS (NRAS) and even Harvey RAS (HRAS) mutations could be predictive markers for treatment with mitogen-activated protein kinase (MEK) inhibitors.
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
GeneRIF
Pao et al., Nashville, United States. In Proc Natl Acad Sci U S A, 2012
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Impact
GeneRIF
Palmieri et al., Italy. In J Clin Oncol, 2012
BRAF/NRAS mutations were identified in 58% of primary melanomas
Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
GeneRIF
Balázs et al., Debrecen, Hungary. In Melanoma Res, 2012
Report marked differences in the genetic pattern of the BRAF or NRAS mutated and wild-type melanoma subgroups.
A comprehensive survey of Ras mutations in cancer.
GeneRIF
Mattos et al., Liverpool, United Kingdom. In Cancer Res, 2012
study examined the mutational spectra of Ras isoforms curated from large-scale tumor profiling and found that each isoform exhibits surprisingly distinctive codon mutation and amino-acid substitution biases
Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma.
GeneRIF
Das et al., Mumbai, India. In Int J Biol Markers, 2012
Investigation the prevalence of mutations in the NRAS gene and its correlation with demographic characteristics, tumor location and stage in 100 colorectal carcinoma patients from India.
share on facebooktweetadd +1mail to friends